162 related articles for article (PubMed ID: 10338905)
1. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
Minshall ME; Liepa AM
Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
[TBL] [Abstract][Full Text] [Related]
2. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
Tennvall GR; Fernberg JO
Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Evans WK
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
[TBL] [Abstract][Full Text] [Related]
5. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Szczepura A
Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
[TBL] [Abstract][Full Text] [Related]
6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S; Goa KL
Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
[TBL] [Abstract][Full Text] [Related]
10. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
Kelly K
Ann Oncol; 1999; 10 Suppl 5():S53-6. PubMed ID: 10582140
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Hansen HH; Sørensen JB
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
[TBL] [Abstract][Full Text] [Related]
12. Economic value of gemcitabine in non-small cell lung cancer.
Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
[TBL] [Abstract][Full Text] [Related]
13. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
14. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
Evans WK
Semin Oncol; 1996 Oct; 23(5 Suppl 10):82-9. PubMed ID: 8893888
[TBL] [Abstract][Full Text] [Related]
15. [Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
Yokoyama A
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1294-300. PubMed ID: 10945029
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine.
Prendiville J; O'Brien M
Br J Hosp Med; 1997 Apr 16-May 6; 57(8):405-9. PubMed ID: 9274666
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
20. Single-agent gemcitabine in non-small cell lung cancer: the French experience.
Le Chevalier T; Gottfried M
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-47-S7-49. PubMed ID: 9194480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
